Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Wed, 26.02.2025
Ina Invest AG
Ad hoc announcement pursuant to Art. 53 LR
Glattpark (Opfikon), 26 February 2025 – Ina Invest achieved total income of CHF 35.6 million in the 2024 financial year. This consists of operating income of CHF 20.2 million and a gain of CHF 15.4 million from changes in market value. Earnings before interest and taxes (EBIT), including changes in market [ … ]
Wed, 26.02.2025
Implenia AG
Increased profitability, all Divisions successful:
EBIT CHF 130.5 million, EBIT margin enhanced to 3.7%
Equity ratio improved to 21.2%; adjusted free cash flow of CHF 58.2 million (excl. Wincasa M&A and above-average net investment in real estate portfolio)
Order book at a high level and of good quality
Industry leader in sustainability
[ … ]
Wed, 26.02.2025
Interroll Holding AG
Sant'Antonino, Switzerland, February 26, 2025. The Board of Directors of Interroll Holding Ltd. has decided to terminate the appointment of CEO Ingo Steinkrüger. He will be replaced by Markus Asch, effective March 1, 2025.
The Chairman of the Board of Directors of Interroll, Paul Zumbühl, is grateful to Ingo Steinkrüger for his tenure: "On behalf o [ … ]
Tue, 25.02.2025
TAG Immobilien AG
PRESS RELEASE
Preliminary results for FY 2024: TAG Immobilien AG exceeds guidance
FFO I in 2024 at EUR 175.1m (guidance: EUR 170-174m)
Net income from sales in Poland at EUR 66.2m in 2024 significantly exceeds the guidance of EUR 46-52m (c. +35%)
FFO II of EUR 239.4m in 2024, is also significantly above the guidance of EUR 217-223m (c. +9%)
[ … ]
Tue, 25.02.2025
TAG Immobilien AG
Net income from sales in Poland and FFO II significantly exceed guidance for FY 2024
Hamburg, 25 February 2025
Based on preliminary and unaudited results, the following guidance was significantly exceeded in the 2024 financial year:
Adjusted net income from sales in Poland: EUR 66.2m, compared to the guidance of EUR 46-52m (c. +35%)
FFO II: EUR [ … ]
Tue, 25.02.2025
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München
The Board of Management of Munich Reinsurance Company intends to propose to the Annual General Meeting a dividend of €20.00 per share for the 2024 financial year (consensus: €16.49). The Supervisory Board is to decide on the Board of Management’s dividend planning once the final business figures are available for 2024. The dividend payment is subje [ … ]
Tue, 25.02.2025
Dr. Ing. h.c. F. Porsche AG
Changes to the Executive Board of Porsche AGPorsche AG initiates long-planned change to its Executive Board
Jochen Breckner takes over from Lutz Meschke as Board Member for Finance and IT with effect from 26 February 2025
Matthias Becker takes over from Detlev von Platen as Board Member for Sales and Marketing with effect from 26 February 2025
S [ … ]
Tue, 25.02.2025
AT&S Austria Technologie & Systemtechnik AG
Appointment of Dr. Michael Mertin as new Chief Executive Officer (CEO) of AT&S AG
Disclosure of inside information pursuant to Article 17 MAR
Leoben – At its meeting today, the Supervisory Board of AT&S decided to appoint Dr. Michael Mertin as member of the Management Board and Chief Executive Officer (CEO) of the company with ef [ … ]
Tue, 25.02.2025
Linde plc
Linde Increases Dividend 8%
Woking, UK, February 25, 2025 – Linde plc (Nasdaq: LIN) today announced its Board of Directors has declared an 8% increase in the company's quarterly dividend to $1.50 per share. This marks the 32nd consecutive year of quarterly dividend increases on the company’s common stock.
The dividend is payable on March 27, 202 [ … ]
Tue, 25.02.2025
Affluent Medical SA
Affluent Medical appoints Liane Teplitsky - a senior executive in the medical device industry as a new member of the Board of Directors
Aix-en-Provence, February 25, 2025 – 5:45 p.m. CET – Affluent Medical (ISIN: FR0013333077 – Ticker: AFME – “Affluent”), a French clinical-stage medical technology company specializing in the international develop [ … ]